NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Novartis
Institute of Hematology & Blood Diseases Hospital, China
University of Michigan Rogel Cancer Center
Goethe University
Norwegian University of Science and Technology